249 related articles for article (PubMed ID: 28942418)
1. Clinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States.
Lassman SM; Shopshear OM; Jazic I; Ulrich J; Francer J
BMJ Open; 2017 Sep; 7(9):e015110. PubMed ID: 28942418
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.
Miller JE; Korn D; Ross JS
BMJ Open; 2015 Nov; 5(11):e009758. PubMed ID: 26563214
[TBL] [Abstract][Full Text] [Related]
3. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
[TBL] [Abstract][Full Text] [Related]
4. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study.
DeVito NJ; Bacon S; Goldacre B
Lancet; 2020 Feb; 395(10221):361-369. PubMed ID: 31958402
[TBL] [Abstract][Full Text] [Related]
5. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.
Phillips AT; Desai NR; Krumholz HM; Zou CX; Miller JE; Ross JS
Trials; 2017 Jul; 18(1):333. PubMed ID: 28720112
[TBL] [Abstract][Full Text] [Related]
6. Trial registration and results disclosure: impact of US legislation on sponsors, investigators, and medical journal editors.
Hirsch L
Curr Med Res Opin; 2008 Jun; 24(6):1683-9. PubMed ID: 18462565
[TBL] [Abstract][Full Text] [Related]
7. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study.
Zou CX; Becker JE; Phillips AT; Garritano JM; Krumholz HM; Miller JE; Ross JS
Trials; 2018 Oct; 19(1):581. PubMed ID: 30352601
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis.
Axson S; Mello MM; Lincow D; Yang C; Gross C; Ross JS; Miller J
BMJ Open; 2021 Jul; 11(7):e053248. PubMed ID: 34281933
[TBL] [Abstract][Full Text] [Related]
9. Compliance with results reporting at ClinicalTrials.gov.
Anderson ML; Chiswell K; Peterson ED; Tasneem A; Topping J; Califf RM
N Engl J Med; 2015 Mar; 372(11):1031-9. PubMed ID: 25760355
[TBL] [Abstract][Full Text] [Related]
10. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study.
Prayle AP; Hurley MN; Smyth AR
BMJ; 2012 Jan; 344():d7373. PubMed ID: 22214756
[TBL] [Abstract][Full Text] [Related]
11. Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA.
Swanson MJ; Johnston JL; Ross JS
Trials; 2021 Nov; 22(1):817. PubMed ID: 34789308
[TBL] [Abstract][Full Text] [Related]
12. Compliance on Mandatory Data Reporting in Registered Obstetrics Trials.
Checketts JX; Evans MB; Athale AH; Jawhar OM; Wright MR; Bryant K; Vassar M
Am J Perinatol; 2018 Oct; 35(12):1192-1196. PubMed ID: 29695018
[TBL] [Abstract][Full Text] [Related]
13. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices.
Miller J; Ross JS; Wilenzick M; Mello MM
BMJ; 2019 Jul; 366():l4217. PubMed ID: 31292127
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial reporting performance of thirty UK universities on ClinicalTrials.gov-evaluation of a new tracking tool for the US clinical trial registry.
Keestra SM; Rodgers F; Lenz D; Osborne R; Bruckner T; Lee S
Trials; 2021 Jun; 22(1):375. PubMed ID: 34074329
[TBL] [Abstract][Full Text] [Related]
16. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
Wallach JD; Egilman AC; Dhruva SS; McCarthy ME; Miller JE; Woloshin S; Schwartz LM; Ross JS
BMJ; 2018 May; 361():k2031. PubMed ID: 29794072
[TBL] [Abstract][Full Text] [Related]
17. ClinicalTrials.gov reporting: strategies for success at an academic health center.
O'Reilly EK; Hassell NJ; Snyder DC; Natoli S; Liu I; Rimmler J; Amspacher V; Burnett BK; Parrish AB; Berglund JP; Stacy M
Clin Transl Sci; 2015 Feb; 8(1):48-51. PubMed ID: 25387802
[TBL] [Abstract][Full Text] [Related]
18. Commitments by the biopharmaceutical industry to clinical trial transparency: the evolving environment.
Baronikova S; Purvis J; Southam E; Beeso J; Panayi A; Winchester C
BMJ Evid Based Med; 2019 Oct; 24(5):177-184. PubMed ID: 30898790
[TBL] [Abstract][Full Text] [Related]
19. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.
Wallach JD; Luxkaranayagam AT; Dhruva SS; Miller JE; Ross JS
BMC Med; 2019 Jun; 17(1):117. PubMed ID: 31203816
[TBL] [Abstract][Full Text] [Related]
20. Overcoming non-compliance with clinical trial registration and results reporting: One Institution's approach.
Snider SH; Flume PA; Gentilin SL; Lesch WA; Sampson RR; Sonne SC
Contemp Clin Trials Commun; 2020 Jun; 18():100557. PubMed ID: 32258818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
